Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module

Research output: Contribution to journalJournal articlepeer-review

Standard

Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. / Piil, Karin; Whisenant, Meagan; Mendoza, Tito; Armstrong, Terri; Cleeland, Charles; Nordentoft, Sara; Williams, Loretta A; Jarden, Mary.

In: Neuro-Oncology Practice, Vol. 8, No. 2, 2021, p. 137-147.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Piil, K, Whisenant, M, Mendoza, T, Armstrong, T, Cleeland, C, Nordentoft, S, Williams, LA & Jarden, M 2021, 'Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module', Neuro-Oncology Practice, vol. 8, no. 2, pp. 137-147. https://doi.org/10.1093/nop/npaa068

APA

Piil, K., Whisenant, M., Mendoza, T., Armstrong, T., Cleeland, C., Nordentoft, S., Williams, L. A., & Jarden, M. (2021). Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. Neuro-Oncology Practice, 8(2), 137-147. https://doi.org/10.1093/nop/npaa068

Vancouver

Piil K, Whisenant M, Mendoza T, Armstrong T, Cleeland C, Nordentoft S et al. Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. Neuro-Oncology Practice. 2021;8(2):137-147. https://doi.org/10.1093/nop/npaa068

Author

Piil, Karin ; Whisenant, Meagan ; Mendoza, Tito ; Armstrong, Terri ; Cleeland, Charles ; Nordentoft, Sara ; Williams, Loretta A ; Jarden, Mary. / Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. In: Neuro-Oncology Practice. 2021 ; Vol. 8, No. 2. pp. 137-147.

Bibtex

@article{059cc8b91fa74d93b4338ef20cc68de3,
title = "Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module",
abstract = "Background: The complexity of disease- and treatment-related symptoms causes profound distress and deterioration of health-related quality of life among patients with brain tumors. Currently, there is no Danish validated disease-specific instrument that focuses solely on measures of both neurologic and cancer-related symptoms of patients with brain tumors. The MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) is a validated patient self-report questionnaire that measures symptom prevalence, intensity, and interference with daily life. The aim of the present study was to determine the psychometric validity of the Danish translation of the MDASI-BT, and to test its utility in 3 cohorts of Danish patients across the spectrum of the brain cancer disease and treatment trajectory.Methods: A linguistic validation process was conducted. Danish patients with malignant primary brain tumors were included to establish the psychometric validity and reliability of the Danish MDASI-BT. Cognitive debriefing interviews were conducted to support the psychometric properties.Results: A total of 120 patients participated in this study. Coefficient αs for the symptom and interference subscales indicate a high level of reliability across all items. Corresponding symptom and interference or functional items and subscales in the MDASI-BT and European Organisation for Research and Treatment of Cancer Brain Tumor Module BN20 were significantly correlated. Cognitive debriefing provided evidence for content validity and questionnaire utility as participants were comfortable answering the questions and had no problem with the understandability or number of questions asked.Conclusion: The MDASI-BT is a simple, concise symptom assessment tool useful for assessing the symptom severity and interference of Danish-speaking patients with brain cancer.",
author = "Karin Piil and Meagan Whisenant and Tito Mendoza and Terri Armstrong and Charles Cleeland and Sara Nordentoft and Williams, {Loretta A} and Mary Jarden",
note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.",
year = "2021",
doi = "10.1093/nop/npaa068",
language = "English",
volume = "8",
pages = "137--147",
journal = "Neuro-Oncology Practice",
issn = "2054-2577",
publisher = "Oxford University Press",
number = "2",

}

RIS

TY - JOUR

T1 - Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module

AU - Piil, Karin

AU - Whisenant, Meagan

AU - Mendoza, Tito

AU - Armstrong, Terri

AU - Cleeland, Charles

AU - Nordentoft, Sara

AU - Williams, Loretta A

AU - Jarden, Mary

N1 - © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PY - 2021

Y1 - 2021

N2 - Background: The complexity of disease- and treatment-related symptoms causes profound distress and deterioration of health-related quality of life among patients with brain tumors. Currently, there is no Danish validated disease-specific instrument that focuses solely on measures of both neurologic and cancer-related symptoms of patients with brain tumors. The MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) is a validated patient self-report questionnaire that measures symptom prevalence, intensity, and interference with daily life. The aim of the present study was to determine the psychometric validity of the Danish translation of the MDASI-BT, and to test its utility in 3 cohorts of Danish patients across the spectrum of the brain cancer disease and treatment trajectory.Methods: A linguistic validation process was conducted. Danish patients with malignant primary brain tumors were included to establish the psychometric validity and reliability of the Danish MDASI-BT. Cognitive debriefing interviews were conducted to support the psychometric properties.Results: A total of 120 patients participated in this study. Coefficient αs for the symptom and interference subscales indicate a high level of reliability across all items. Corresponding symptom and interference or functional items and subscales in the MDASI-BT and European Organisation for Research and Treatment of Cancer Brain Tumor Module BN20 were significantly correlated. Cognitive debriefing provided evidence for content validity and questionnaire utility as participants were comfortable answering the questions and had no problem with the understandability or number of questions asked.Conclusion: The MDASI-BT is a simple, concise symptom assessment tool useful for assessing the symptom severity and interference of Danish-speaking patients with brain cancer.

AB - Background: The complexity of disease- and treatment-related symptoms causes profound distress and deterioration of health-related quality of life among patients with brain tumors. Currently, there is no Danish validated disease-specific instrument that focuses solely on measures of both neurologic and cancer-related symptoms of patients with brain tumors. The MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) is a validated patient self-report questionnaire that measures symptom prevalence, intensity, and interference with daily life. The aim of the present study was to determine the psychometric validity of the Danish translation of the MDASI-BT, and to test its utility in 3 cohorts of Danish patients across the spectrum of the brain cancer disease and treatment trajectory.Methods: A linguistic validation process was conducted. Danish patients with malignant primary brain tumors were included to establish the psychometric validity and reliability of the Danish MDASI-BT. Cognitive debriefing interviews were conducted to support the psychometric properties.Results: A total of 120 patients participated in this study. Coefficient αs for the symptom and interference subscales indicate a high level of reliability across all items. Corresponding symptom and interference or functional items and subscales in the MDASI-BT and European Organisation for Research and Treatment of Cancer Brain Tumor Module BN20 were significantly correlated. Cognitive debriefing provided evidence for content validity and questionnaire utility as participants were comfortable answering the questions and had no problem with the understandability or number of questions asked.Conclusion: The MDASI-BT is a simple, concise symptom assessment tool useful for assessing the symptom severity and interference of Danish-speaking patients with brain cancer.

U2 - 10.1093/nop/npaa068

DO - 10.1093/nop/npaa068

M3 - Journal article

C2 - 33898047

VL - 8

SP - 137

EP - 147

JO - Neuro-Oncology Practice

JF - Neuro-Oncology Practice

SN - 2054-2577

IS - 2

ER -

ID: 261615750